| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Darolutamide | Nubeqa | 300mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2019 | In Use | |||
| NA | Belumosudil | Rezurock | 200mg | Chemotherapy | Rho Kinase Inhibitor | ROCK1, ROCK2 | Yes | 2021 | In Use | |||
| NA | Cyclosporine | NeOral | 25mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 1995 | In Use | |||
| NA | Imiquimod | Aldara | 5% | Immunotherapy | Immunomodulator | Retinoic Acid Derivative | No | 1997 | In Use | |||
| NA | Pomalidomide | Pomalyst | 1 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
| NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
| N/A | Zongertinib | HERNEXEOS | 60mg | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Yes | 2025 | In Use | |||
| NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| NA | Bexarotene | Targretin | 75mg | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | Yes | 2014 | In Use | |||
| NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
| NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
| NA | Uridine Triacetate | Xuriden | 2 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
| NA | Lapatinib | Tykerb | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Yes | 2007 | In Use | |||
| NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
| NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
| NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
| NA | Axitinib | Axitinib | 5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | Estrogens, Conjugated | Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) | multiple | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
| NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | Cysteamine Bitartrate | Procysbi | 25mg, 75mg, 300mg | Chemotherapy | Cystine-Depleting Agent | Yes | 2013 | In Use | ||||
| NA | Enasidenib mesylate | Idhifa | 100 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
| NA | Nintedanib | Ofev | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
| NA | Avapritinib | Ayvakit | 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| NA | Erdafitinib | Balversa | 3mg, 4mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Yes | 2019 | In Use | |||
| Niraparib and Abiraterone | Akeega | Multiple | Chemotherapy | Androgen Receptor Inhibitor, Enzyme Inhibitor | CYP 17, PARP | Yes | 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home